The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the top low volatility healthcare stocks to buy now. On July 24, Goldman ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

This was the stock's fifth consecutive day of losses.

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

Bristol-Myers Squibb Company (NYSE:BMY) is scheduled to announce Q2 earnings results on July 31st, before markets open.

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

Novo Nordisk promoted Maziar Mike Doustdar to president and CEO, effective August 7. The Food and Drug Administration tapped newly appointed George Tidmarsh as acting Center for Biologics Evaluation ...

Explore the exciting world of Bristol Meyers Squibb (NYSE: BMY) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into ...

Our Bristol Myers Squibb Operating Income Comparison dashboard has more details. The company’s earnings stood at $2.97 on a per-share and reported basis in 2022, compared to the $2.02 figure in ...

Bristol Myers Squibb’s revenue of $11.9 billion in Q2 was up 2% y-o-y, and its EPS of $1.93 reflected an 18% growth. This compares with our estimates of $11.5 billion and $1.86, respectively.